The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I, dose-escalation study of the investigational drug TAK-733, an oral MEK inhibitor, in patients (pts) with advanced solid tumors.
Alex A. Adjei
No relevant relationships to disclose
Patricia LoRusso
Consultant or Advisory Role - Millennium
Research Funding - Millennium
Antoni Ribas
Consultant or Advisory Role - Amgen; Genentech; GlaxoSmithKline; Merck; Millennium; Novartis
Stock Ownership - Kite Pharma
Honoraria - Millennium
Jeffrey Alan Sosman
Consultant or Advisory Role - Millennium
Honoraria - Millennium
Anna C. Pavlick
No relevant relationships to disclose
Grace K. Dy
No relevant relationships to disclose
Xiaofei Zhou
Employment or Leadership Position - Millennium
Esha A. Gangolli
Employment or Leadership Position - Millennium
Stock Ownership - Novartis; Takeda
Russell M Walker
Employment or Leadership Position - Millennium
Stock Ownership - Millennium
Michelle Kneissl
Employment or Leadership Position - Millennium
Stephanie Faucette
Employment or Leadership Position - Millennium
Rachel Neuwirth
Employment or Leadership Position - Millennium
Viviana Bozon
Employment or Leadership Position - Millennium